Drug Discovery Capabilities of ArQule, Inc. Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today presented data at the AACR-NCI-EORTC meeting in Boston demonstrating the capabilities of the Company’s proprietary drug discovery platform to generate a class of small molecules with significant therapeutic potential.